Biotech ETF Overview

No one U.S. biotech ETFs provides comprehensive, unbiased access to the space. Instead, each captures a piece of it—and of related industries like pharmaceuticals and medical. Tread carefully here, as each fund defines biotech differently, and the differences have material impacts on performance: In some years, the difference between the best-performing and the worst-performing biotech ETF exceeds 15%. The good news is that most of these biotech ETFs are relatively efficient and liquid.

Daily Hot Reads

Friday Hot Reads: Why Bogle Doesn’t Fly First Class

Also, biotech stocks break out.

Features and News

15 Most Shorted ETFs

Investors are betting heavily against these exchange-traded funds.

Features and News

2 Key Drivers Behind Biotech ETF Rally

The segment is delivering some impressive gains after a bout of investor doubt.

Weekly ETF Flows

Int'l Equity & Biotech ETFs Fuel Weekly Inflows

U.S.-listed ETFs took in $3.6 billion in new money in the latest week.

Daily Hot Reads

Friday Hot Reads: Biotech ETFs Heating Up

What biotech ETFs to consider now, and a look at the resilience of dividend ETF investors.

Weekly ETF Flows

Weekly Inflows Slow To A Trickle

Inflows into U.S.-listed ETFs were positive, but they fell significantly from the lofty levels of the past few weeks. Analysis

Similar Sector ETFs Not Built The Same

Issuers take different approaches to industry and sector exposure.

Daily ETF Flows

S&P 500 ETFs Pull In $7.3 Billion

S&P 500 Index ETFs from State Street, iShares and Vanguard pulled in a total of $7.3 billion on Tuesday.

Features and News

Why Health Care Is The Top Sector Of 2017

Health care ETFs have largely shrugged off the Republican health care bill.